Understanding how Ewing Sarcoma cells avoid natural defenses
Official title: Mechanisms underlying USP1-mediated bypass of EWS-FLI1 oncogene-induced replication stress in Ewing sarcoma
Funded at University of Nebraska Medical Center · NIH-11139515 · Data updated 2026-11-12
This research explores how Ewing sarcoma cancer cells manage to keep growing even when they should stop or die, focusing on a protein called USP1.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $351,131 |
| NIH project number | 5R01CA263504-04 |
| Project ID | NIH-11139515 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is for future patients with Ewing sarcoma, as it aims to uncover new treatment strategies for this specific type of bone cancer.
✕Less likely to help
Patients with other types of cancer or conditions not related to Ewing sarcoma may not directly benefit from this specific research.
What this research studies
Normally, our bodies have ways to stop cancer cells from growing out of control, like making them age or die when they have too much stress. However, Ewing sarcoma cells find a way around these natural defenses, allowing them to multiply unchecked. This project aims to uncover the specific ways these cancer cells bypass these protective systems. We are particularly interested in a protein called USP1, which appears to be overactive in Ewing sarcoma and might be helping these cells survive. By understanding this process, we hope to find new ways to target and treat this aggressive bone cancer.
Why it matters
Potential benefit: If successful, this research could identify new targets for medications that could stop Ewing sarcoma cells from growing, potentially leading to more effective treatments.
How similar studies have gone: While the specific mechanism being studied is largely unknown, preliminary data from this team suggests that the USP1 protein is involved in Ewing sarcoma.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Ghosal, Gargi — University of Nebraska Medical Center
- Study coordinator: Ghosal, Gargi
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.